S&P 5007,675.92▼0.4% Nasdaq26,749.30▼0.7% Dow51,245.74▼0.5% Russell 2K2,826.40▼0.4% 10-Yr5.12%+1bp VIX15.69+0.51 WTI$95.27▲3.4% Gold$4,292.50▼0.6% EUR/USD1.138▼0.6% BTC$83,940▼0.5% Nikkei65,514▲0.8%
At close · Thu, Sep 24, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Novo’s obesity drug outlook faces Eli Lilly competition

Novo’s obesity drug outlook faces Eli Lilly competition

Reported · Written up by our desk · Previews

CNBC Markets reports that Novo Nordisk is working to turn around its business as Eli Lilly increases its share in GLP-1 obesity drugs.

The article says some analysts believe Lilly has advantages that could help the company maintain its leading position in the obesity drug market, even as Novo tries to move into its next phase.

← Newer storyYen stays range-bound vs dollar as intervention risk looms

More like this

EarningsDiamondback shares slide after downgrade, block sale as oil supports hold
EarningsBlackBerry lands $100 million-plus QNX deal ahead of Q2 earnings
EarningsSuper Micro Computer ships NVIDIA Vera Rubin liquid-cooled racks
EarningsSpaceX plans to end shared Falcon 9 missions after 2028
EarningsDave stock drops after earnings despite rising revenue and margins

Sources

CNBC MarketsNovo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.